Cytoprotective Agent RNS60 Receives Fast Track Designation for Ischemic Stroke Treatment
Revalesio's RNS60 gains FDA fast track status, offering a groundbreaking approach to neuroprotection in ischemic stroke treatment.
Previous Post
Fake WHO, Abbott Emails Used in Over Rs 1.1 Crore Scam on Pharma Executive, 2 Nabbed
Next Post
First global guidelines for pregnancy and inflammatory bowel disease developed
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago